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developing countries, measles has a high morbidity in under-
nourished children and appears to be one of the events that can
trigger acute xerophthalmia.2 Moreover, recent work in Africa has
indicated that malnourished children frequently acquire herpes
simplex virus eye infections after measles.3 There is also now
experimental work to show that vitamin-A-deficient rabbits, but not
control animals, are very susceptible to corneal ulceration from
bacterial infection.4 Some blinding infections of childhood, which
are so common in certain developing countries, must have a
nutritional component. The annual incidence of 2 - 7 cases/1000 of
classic corneal xerophthalmia determined by Sommer et al. reflects
only blindness attributable to typical severe vitamin-A deficiency
and may be only a fraction of the total contribution of malnutrition
to blindness.
The prevention of avoidable childhood blindness in developing
countries should be based on a multifactorial approach which
includes better nutrition (with vitamin A supplementation where
appropriate), improved water supplies and hygiene, easily available
antibiotics to treat minor eye infections, and systematic measles
vaccination.
W.H.O. Collaborating Centre for Prevention
of Blindness and Trachoma,
and Francis I. Proctor Foundation
for Research in Ophthalmology,
University of California,





SIR,-Inge Gurevich and Dr Cunha (Aug. 1, p. 222) report "... the
first documented cases of CMV infection caused by non-parenteral
transmission of CMV within a nursery". Their claim, if true, has
important implications for all hospital personnel who care for sick
babies. Unfortunately, they do not present a rigorous argument to
substantiate their claim. Although CMV inclusion bodies are one
indication of possible CMV infection, no viral cultures were done in
this epidemiological study. CMV cultures are routine in any
hospital viral diagnostic laboratory, and could have been done on
urine samples in suspect cases or on post-mortem tissue.
Most striking, however, is Gurevich and Cunha’s failure to
acknowledge several reports of the high frequency of CMV
acquisition by infants who have spent a long time in a neonatal
intensive care unit (NICU).5-7 From 14 to 30% of all infants older
than 3 weeks of age in nurseries become culture-positive for CMV
The frequency of CMV serological positivity in these infants may
well be higher. CMV acquisition by such infants is greatly
dependent upon the number of different blood donors from whom
an infant receives blood and the amount of blood an infant receives.
When infants born to CMV-negative mothers are transfused with
CMV-negative blood, acquisition of the virus can be eliminated.8,9
The infants described by Gurevich and Cunha could have acquired
their CMV infections through blood transfusions or by passing
through an infected cervix during delivery.
Over the past 3 years I have studied the epidemiology of CMV
infections in three different NICUS. 10 Although most cases of CMV
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infection were sporadic, our surveillance programme has identified
clusters of two to four infants excreting CMV at the same time in
one NICU. I agree that these multiple groups of infants with
temporally related nosocomial CMV infections suggest that infant-
infant transmission of CMV may occur. To help resolve this
question, I have made use of restriction endonuclease digestion
analyses to compare the DNA fragment migration patterns of the
CMV isolates of infants with apparently epidemiologically related
infections. So far these analyses indicate that no two infants
excreting CMV were infected with the same virus strain.
Unfortunately, Gurevich and Cunha do not have the CMV isolates
available on which to do restriction enzyme digestion analysis.
Confirmation of non-parenteral transmission of CMV in a NICU is
therefore lacking.
I share with these workers concern for the possible transmission
of CMV from an infected infant to other babies or to nursery
personnel. As yet, however, there is no eivdence that such
transmission has occurred.
Division of Infectious Disease,
University Hospital,
San Diego, California 92103, U.S.A.;
and Department of Pediatrics,
University of California, San Diego STEPHEN A. SPECTOR
SIR,-Inge Gurevich and Dr Cunha’s presentation is consistent
with their conclusion that the index infant was the source ofnon-
parenteral transmission of the virus to four other infected infants,
but it seems equally consistent with the possibility that the other
four infants acquired CMV independently, from other potential
reservoirs that were noted elsewhere in the article. One unit of fresh
blood was shared by the investigated infants and the donor was
seronegative. Was this the only donor used for all the infants during
their hospital stays? If not, transfusion of live virus or of latently
infected cells with subsequent reactivation has not been ruled out.
Inadequate information is supplied to rule out the possibility that
infants 3 and 5 acquired their infections at birth from infected
maternal secretions at delivery. Was non-pasteurised maternal or
donor breast milk fed to any of the infants? If so, evaluation of the
donors would be necessary to rule out the possible source of
transmission. In the absence of such information, it is not clear to
me that CMV transmission was from the index patient or non-
parenteral. Restriction endonuclease analysis of the viral DNA in
the index case and the other four infected infants would be a
stronger tool for assessment of common viral origin and possible
routes of transmission. 1,2
Section of Newborn Services,
Women’s Hospital,
and University of Michigan,
Ann Arbor, Michigan 48109, U.S.A. ROGER G. FAIX
*The Nassau Hospital workers’ response follows.-ED.L.
SiR,-Comments on the value of restriction-enzyme analysis for
establishing a common source for the CMV encountered in our
nursery are well taken. We were unable to pursue that aspect
because CMV was not suspected and specimens were not obtained
at necropsy of cases 2 and 3. Suspicion of a "cluster" was not
aroused until the mother of the twins demonstrated a negative titre
while the surviving twin had a raised titre (1:640), and they were not
confirmed until the titres from cases 5 were evaluated. By that time,
the earlier serum specimens were no longer available.
All infants received multiple transfusions and it is possible, but
not very probable, that such a variety of donors would all be CMV
carriers. Similarly, some of the infants were fed mother’s milk, but
again it would be unlikely that a synchronous outbreak would occur
from such varied sources.
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While we agree that our conclusions are not proven beyond doubt,
the temporal proximity of the cases to the index case plus that fact
that this is the first such cluster in a nursery, makes this hypothesis
the best explanation for what happened. We hope that scientific
studies will be directed at either proving or disproving the theory
that CMV can be transmitted within nurseries by means other
than breast milk and transfusions of blood products.
Infectious Diseases Division,
Nassau Hospital,
Long Island, N.Y. 11501, U.S.A.
BURKE A. CUNHA
INGE GUREVICH
DUAL EFFECT OF SULPHASALAZINE ON COLONIC
PROSTAGLANDIN SYNTHETASE
SiR,-Dr Hoult and Helen Page (Aug. 1, p. 255) describe
enhanced release of colonic mucosal prostaglandins (PG) in the
presence of submillimolar concentrations of 5-aminosalicylic acid
(5-ASA), the colonic metabolite of sulphasalazine (SASP). They
suggest that 5-ASA acts as a co-factor for PG biosynthesis and that
increased PG production might add to the inhibition of PG degrada-
tion by the parent SASP, both mechanisms possibly lowering
colonic PG levels during SASP therapy.
We have studied the effect of SASP on PG synthesis by a
microsomal fraction of human colonic mucosa using various
concentrations of arachidonic acid as substrate. Enzyme
preparation, incubation, and radioimmunological determination of
PG were as described previously. As shown in the figure, SASP has
a dual effect on human colonic PG synthetase depending on the
concentration of arachidonic acid used. Only at high substrate
concentrations did ASAP (0-25 mmol/1) stimulate formation of
:-PGE2 from arachidonic acid: at low substrate concentrations the
same concentration of SASP inhibits PGE2 synthesis. At a given
concentration of arachidonic acid the effects are dose-dependent for
SASP.
In further experiments human colonic mucosa was cut into small
pieces, washed, and incubated as whole cell preparations The
incubation medium was analysed for PGE2 and its 15-keto-13,
14-dihydrometabolite (KH2PGE2). During a 6 min incubation
period SASP (0-25 mmol/1) increased mucosal PGE2 release by
127&plusmn;31% (mean&plusmn;SEM, n=12). Simultaneously, enhanced
formation of the metabolite KH2 PGE2 occurred (96&plusmn;41%, n=7),
indicating that the increase in PGE2 release was due not to
inhibition of PG degradation but to stimulated biosynthesis.
1. Peskar BM. On the synthesis of prostaglandins by human gastric mucosa and its
modification by drugs. Biochim Biophys Acta 1977; 487: 307-14.
2 Peskar BM, Seyberth HW, Peskar BA. Synthesis and metabolism of endogenous
prostaglandins by human gastric mucosa. In: Samuelsson B, Ramwell PW, Paoletti
R, eds. Advances in prostaglandin and thromboxane research: Vol VIII. New York:
Raven Press, 1980: 1511-14.
Effect of SASP (0-25 mmolll) on human colonic PG synthetase in
presence of various concentrations of arachidonic acid.
Incubations were for 10 min. Values are the mean&plusmn;SEM of 5 experiments.
Our results show that, as for 5-ASA (Hoult and Page), the parent
SASP can strongly stimulate endogenous mucosal PG synthesis.
However, the effect of SASP on PG synthetase is clearly dependent
on the concentration of the substrate arachidonic acid. In intact cells
the concentration of free arachidonic acid at the site of cyclo-
oxygenase is controlled by the activity of phospholipase A2. This
enzyme might, therefore, play a crucial role in determining the
effect of SASP on PG synthesis. Stimulation of PG formation
observed in short time incubation experiments with whole cell
preparations could be due to excess activity of phospholipase A 2
(induced, for example, by mechanical irritation3) which in turn
leads to high concentrations of free arachidonic acid not necessarily
reflecting in situ conditions. As the activity of phospholipase A2
may vary in different cells of the gastrointestinal tract and especially
with different stages of chronic inflammatory bowel disease we
propose that the effect of SASP on PG synthesis in vivo may vary
from inhibition to stimulation depending on the local concentration
of the substrate fatty acid. Sharon et a1.4 have found inhibition of
PG production by SASP and 5-ASA during 24 h incubation
experiments with human rectal mucosa. Similarly, Smith et
a1.5 reported reduced PG synthesis by human rectal mucosal
homogenates in the presence of SASP.
The dual effect of SASP inducing at the same drug concentration
stimulation or inhibition of PG biosynthesis depending on the
concentration of free arachidonic acid could possibly explain the
lack of effect of SASP administration on net mucosal PG production
in vivo.6 Furthermore, it could correlate to the varying efficacy of
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SORBITOL, PROSTAGLANDINS, AND ULCERATIVE
COLITIS ENEMAS
SIR,-There has been a lot of interest lately in the role of
sulphasalazine in the prostaglandin (PG) metabolism of patients
with ulcerative colitis. Enhanced prostaglandin production was
observed by measurements in urine,8 stool,9 and rectal mucosa.l0 In
patients sulphasalazine inhibits prostaglandin production, 11 and this
has been confirmed in vitro. 12,13 As I have chronic ulcerative colitis-
and have for some years worked in prostaglandin research-
I measured PG levels on samples of my own stool over a 10 day
period, according to the method of Gould.9 The figure shows the
measured PG-like activity, determined on rat stomach strip in a
superfused cascade system.l4,ls
3. Flower RJ, Blackwell GJ. The importance of phospholipase-A2 in prostaglandin
biosynthesis. Biochem Pharmacol 1976; 25: 285-91
4. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative
colitis: Enhanced production during active disease and inhibition by sulphasalazine.
Gastroenterology 1978; 75: 638-40.
5. Smith PR, Dawson DJ, Swan CHJ. Prostaglandin synthetase activity in acute
ulcerative colitis: Effect of treatment with sulphasalazine, codeine phosphate and
prednisolone. Gut 1978; 20: 802-05.
6. Rampton DS, Sladen GE. The effect of sulphasalazine withdrawal on rectal mucosal
function and prostaglandin E2 release in inactive ulcerative colitis Scand J Gastro-
enterol 1981; 16: 157-59.
7. Goldman P, Peppercorn MA Sulfasalazine. N Engl J Med 1975; 293: 20-23.
8. Gould SR, Brash AR, Conolly ME Increased prostaglandin production in ulcerative
colitis. Lancet 1977; ii: 98.
9. Gould SR. Assay of prostaglandin-like substances in faeces and their measurement in
ulcerative colitis. Prostaglandins 1976; 11: 489-97
10. Sharon P, Ligumsky M, Rachmilewitz D, Zor U Role of prostaglandins in ulcerative
colitis. Enhanced production during active disease and inhibition by sulfasalazine.
Gastroenterology 1978; 75: 638-40.
11. Gould SR, Brash AR, Conolly ME, Lennard-Jones JE. Studies of prostaglandins and
sulphasalazine in ulcerative colitis. Prostaglandins Med 1981; 6: 165-82
12. Hoult JRS, Moore PK. Sulphasalazine is a potent inhibitor of prostaglandin
15-hydroxydehydrogenase: Possible basis for therapeutic action in ulcerative colitis.
Br J Pharmacol 1978; 64: 6-8
13. Hoult JRS, Moore PK, Ramcharan E. Sulphasalazine inhibits the pulmonary inacti-
vation of prostaglandins in the rat m vivo. Br J Pharmacol 1979; 66: 101P-102P.
14. Vane JR. The use of isolated organs for detecting active substances in the circulating
blood. Br J Pharmacol Chemother 1964; 23: 360-73.
15. Zijlstra FJ, Vincent JE. Contractile characteristics of the rat stomach strip and the
rabbit aorta and mesenteric artery. J Pharmacol Meth 1981; 6: 1-4.
